The physiological role of phosphodiesterase (PDE)11 is unknown and its biochemical characteristics are poorly understood. We have expressed human His-tagged PDE11A4 and purified the enzyme to apparent homogeneity. PDE11A4 displays K m values of 0.97 lM for cGMP and 2.4 lM for cAMP, and maximal velocities were 4-to 10-fold higher for cAMP than for cGMP. Given the homology between PDE11 and PDE5, we have compared the biochemical potencies of tadalafil (Cialist, Lilly-ICOS), vardenafil (Levitrat, Bayer-GSK), and sildenafil (Viagrat, Pfizer Inc.) for PDE11A4 and PDE5A1. PDE5A1/PDE11A4 selectivities are 40-, 9300-, and 1000-fold for tadalafil, vardenafil, and sildenafil, respectively. This suggests that none of these three compounds is likely to crossreact with PDE11A4 in patients.
Introduction
The cyclic nucleotides (CNs), cAMP and cGMP, are second messengers that are of particular import in cellular signaling. The CNs are involved in the regulation of most physiological processes and have multiple intracellular targets in mammals including CN-gated channels, guanine nucleotide exchange factors, CN-specific phosphodiesterases (PDE), CNbinding PDEs, and CN-dependent protein kinases. Cellular CN levels are modulated by changes in the rate of CN synthesis by adenylyl or guanylyl cyclases and the rate of CN breakdown by PDEs. The PDEs are a superfamily of metallophosphohydrolases that catalyze the hydrolysis of the CNs to their respective 5 0 noncyclic forms. Hydrolysis of CNs by PDEs provides the major cellular mechanism for the dampening of cellular CN signaling; it is therefore of great interest to determine the biochemical characteristics that provide for interaction of PDEs with CNs and related ligands. [1] [2] [3] [4] [5] The mammalian PDE superfamily currently consists of 11 members that preferentially hydrolyze cAMP (PDE4, PDE7, PDE8) or cGMP (PDE5, PDE6, PDE9) or both cAMP and cGMP (PDE1, PDE2, PDE3, PDE10, PDE11). 5 PDE11 is the most recently described member of this superfamily, and its biochemical characteristics and physiological roles are poorly understood. Research focused on the PDE superfamily has proved to be of great consequence in the treatment of numerous human maladies and disease. Specific inhibitors of members of the PDE superfamily are currently being investigated for treatment of asthma, acute ischemic stroke, cancer, systemic inflammation, pulmonary hypertension, and many others. 5, 6 PDE inhibitors have been approved for clinical use in the treatment of intermittent claudication, congestive heart failure, chronic obstructive pulmonary disease and erectile dysfunction. 6 Given the therapeutic implications of PDEs, there is strong precedence for investigations of poorly understood members such as PDE11.
Four human PDE11 variants (PDE11A1-A4) have been reported ( Figure 1) ; these arise from a single gene and hydrolyze both cAMP and cGMP. [7] [8] [9] [10] [11] All PDE11 variants contain a conserved C-terminal catalytic domain and an N-terminal regulatory domain of varying lengths. By mRNA analysis, PDE11 variants demonstrate tissue-specific expression with PDE11A1 being present in skeletal muscle, PDE11A3 in testis, and PDE11A4 in the prostate gland. 7, 9, 10 Of the four PDE11A variants, PDE11A4 contains the most extensive regulatory domain structure, suggesting the possibility that this variant is both highly regulated and plays an important physiological role.
The N-terminal regulatory region of PDE11A4 contains two GAF domains (cGMP-binding PDEsanabaena adenylyl cyclase-Fhla transcription factor) as well as two consensus phosphorylation sites for protein kinase A (PKA) and protein kinase G (PKG), although functional effects of either region have not been demonstrated. 10 The amino-acid sequence of the catalytic domain of PDE11 is approximately 51% identical with that of the catalytic domain of PDE5, 9 suggesting the possibility that commercially available PDE5 inhibitors might crossreact with PDE11. An initial study reported a relatively low selectivity (five-fold) of tadalafil for PDE5 over PDE11A1. 12 It has been suggested that PDE11 inhibition could account for the back pain and myalgia reported by some men taking tadalafil, as well as for alterations in spermatogenesis seen in dogs given tadalafil daily. [13] [14] [15] Interestingly, other PDE5 inhibitors have also been reported to cause similar side effects such as myalgia, 16 and a recent study concluded that there was no effect of tadalafil on spermatogenesis in men.
14 Herein, we present biochemical evidence comparing the potencies of tadalafil, vardenafil, and sildenafil for PDE11A4, and the fold selectivity of these inhibitors for PDE5A1 over PDE11A4.
Methods and Results

Expression and purification of recombinant human PDE11A4
The cDNA clone encoding human PDE11A4 was a generous gift from Tanabe Seiyaku Co., Ltd (Saitama, Japan). To generate an expression plasmid for fulllength PDE11A4, this cDNA was amplified by High Fidelityt PCR System (Roche Molecular Biochemicals) using the forward primer, PDE11A4For (5 0 -GTAGTCGACATGGCAGCCTCCCGCCTGGAC-3 0 ) and the reverse primer, PDE11A4Rev (5 0 -GTAGTCTCGAG TTAGTTCCTGTCTTCCTTG-3 0 ), containing an SalI and XhoI restriction site (underlined) and the original start and termination codons (bolded). The resulting PCR fragment of 2825 bp was cloned into pCR-2.1 TOPOt (Invitrogen) and verified by DNA sequencing. The insert was then excised by digestion with SalI and XhoI and cloned into the pFastBact HTc vector (Invitrogen), which was linearized by digestion with SalI and XhoI and then ligated after the addition of the fragment. This yielded the expression plasmid for full-length His-tagged human PDE11A4 termed His-hPDE11A4. This expression plasmid was then used to generate a recombinant baculovirus according to the protocol in the Bac-to-Bac Baculovirus Expression System manual (Invitrogen). For large-scale protein production, Sf9 (Pharmingen) cells were grown in spinner flasks in Grace's insect media with 10% fetal bovine serum, 0.06 mg/ml gentamycin, and 100 mM 3-isobutyl-1-methylxanthine to a density of 1 Â 10 6 cells/ ml, and then infected for 4 days at 271C with the optimal amount of virus. Cells were harvested by low-speed centrifugation and suspended in ice-cold lysis buffer (20 mM Tris-HCl, pH ¼ 8.0, 100 mM NaCl) containing a mixture of protease inhibitors (Protease Complete tablets, Roche Molecular Biochemicals). Cells were then lysed at 41C by 2 Â 4-s bursts using an Ultraturrax homogenizer (Tekmar). Cell lysate was clarified by centrifugation at 41C for 20 min at 10 000 r.p.m. in a Beckman JA-20 rotor. A measure of 1 ml of Ni-NTA agarose beads (Qiagent) was then poured into a 0.8 Â 0.9 cm 2 column (Pharmacia Biotech) kept at 41C and the column was washed with 100 ml of ice-cold lysis buffer. The cell lysate supernatant was then passed over the column twice and the column was washed exten- Selectivity of PDE5 inhibitors for PDE5 over PDE11 JL Weeks et al sively with lysis buffer containing a stepwise gradient of imidazole from 0.8-20 mM. Protein was eluted from the column with lysis buffer containing 100 mM imidiazole and individual fractions were collected. PDE activity assays were performed as described 17 on eluted fractions and fractions containing PDE activity were pooled together and dialyzed against 700 volumes of 10 mM potassium phosphate buffer, pH 6.8, containing 25 mM b-mercaptoethanol (KPM) for 48 h. After dialysis, the enzyme was quick-frozen using liquid nitrogen in an aqueous solution containing 10% sucrose and 150 mM NaCl and stored at À801C until use. Human PDE5A1 was expressed and purified as described. 17 Relative protein concentrations were determined by the Bradford method 18 using bovine serum albumin (BSA, Sigma) as a standard. Using this purification scheme, PDE11A4 was purified to apparent homogeneity as assessed by SDS-PAGE followed by Coomassie Blue staining. The enzyme migrated with a molecular weight of approximately 100 kDa (Figure 2) , which was consistent with the predicted molecular weight of 105 kDa based on amino-acid composition and with that of partially purified PDE11A4 reported previously. 10 Western blotting with a polyclonal antibody against the Nterminal region of PDE11A3 and PDE11A4 revealed a single band that comigrated with the 100 kDa band on SDS-PAGE (Figure 2 ). The polyclonal antibody generated against the N-terminal regions of PDE11A3 and PDE11A4 was a generous gift from Tanabe Seiyaku Co., Ltd (Saitama, Japan) and was used at dilutions from 1:1000 to 1:5000.
Kinetic analysis of human PDE11A4
Studies of PDE catalytic activity were performed using [ H]cGMP were from Amersham Biosciences. The reaction mixtures were incubated at 301C for 10 min and terminated by the addition of 20 ml of stop mix (143 mM EDTA, 60 mM theophylline, 30 mM cAMP, 30 mM cGMP, and 286 mM Tris-HCl, pH 7.5) and the tubes were transferred to an ice-water bath. Next, snake venom nucleotidase (200 mg, Sigma) was added to each tube and reactions were incubated for 10 min at 301C, after which the tubes were transferred to an ice-water bath and 1 ml of ice-cold dilution solution (0.1 mM adenosine, 0.1 mM guanosine, and 15 mM EDTA) was added. The reaction mixtures were then applied to 2.1 mL QAE-Sephadex (Pharmacia) anion-exchange columns that had been equilibrated with 0.02 M ammonium formate, pH 7.5, and the flow-through was collected. The columns were then washed with 2 ml of 0.02 M ammonium formate, pH 7.5, and this flow-through was also collected and combined with the first flowthrough. The combined eluates were then placed in scintillation fluid and counted in a scintillation counter. Counts per minute were converted to pmol of CN hydrolyzed/min/ml of enzyme. The nonlinear regression function of GraphPad Prism was then used to analyze the data and determine the K m and maximal velocities.
The K m values of purified human PDE11A4 were 2.470.96 mM for cAMP and 0.9770.08 mM for cGMP, which agreed well with those reported previously. 10 Error values are standard error of the mean of values from at least two experiments, each of which was performed in triplicate. In all experiments performed, maximal velocities for PDE11A4 were fourto 10-fold higher for cAMP than for cGMP (Figure 3) . Recombinant human His-tagged PDE11A4 was purified to apparent homogeneity on SDS-PAGE as described in Methods and Results and migrated with an apparent molecular weight of 100 kDa. Lane 1 shows low-molecular-weight standards with molecular weight (in kDa) shown to the left. Lane 2 contains 1 mg of purified PDE11A4. Western blot analysis of purified human PDE11A4 (lane 3) revealed a single band that comigrated with the purified protein shown in lane 2.
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Biochemical potency of CNs and CN analogs for inhibition of PDE11A4 and PDE5A1
The IC 50 values (inhibitor concentration at 50% inhibition) for cAMP, cGMP, sildenafil, tadalafil, vardenafil, and dipyridamole were determined for PDE11A4 using the PDE catalytic activity assay with cGMP as substrate. The assay was performed as described above, using a final concentration of labeled and unlabeled cGMP of 100 nM (80 nM [ 3 H]cGMP and 20 nM cGMP). This concentration of cGMP was approximately 10 times below the apparent K m for cGMP and ensured that the IC 50 value approximated the K i value. [19] [20] [21] Sildenafil was purified from Viagrat tablets as described. 22 Tadalafil was synthesized in-house as described. 17 Vardenafil was a generous gift from Bayer Inc. Dipyridamole was obtained from Sigma. All drugs were diluted serially in Milliporet water from their respective stock solutions. CN stock solutions were prepared in Milliporet water. Stock dipyridamole, vardenafil, and tadalafil were prepared in 100% DMSO and stock sildenafil was prepared in 100% ethanol. The highest concentrations of either DMSO or ethanol used in the assay did not affect catalytic activity (not shown). Reactions were started by the addition of 10 ml of PDE11A4 (final concentration was 2.1 nM) diluted in KPM-BSA and the catalytic assay was performed as described above. The IC 50 values were calculated using GraphPad Prism software. The concentrations of inhibitors were selected so that nearly 100% inhibition was attained in each experiment. Table 1 shows the IC 50 of each of the three PDE5 inhibitors for purified recombinant human PDE11A4. Error values are standard error of the mean and represent at least two experiments, each performed in triplicate. Of the commercially available PDE5 inhibitors, tadalafil was the most potent for PDE11A4 with an IC 50 value of 73 nM. Vardenafil and sildenafil demonstrated a 4.5-fold difference in potency for PDE11A4, with IC 50 values of 840 and 3800 nM, respectively. A difference between vardenafil and sildenafil was also reported for PDE5A1, where the IC 50 of vardenafil was markedly lower than that of sildenafil. 17 The IC 50 values for cGMP and cAMP were 560 and 1200 nM, respectively, which were in reasonable agreement with K m values for these nucleotides. The PDE inhibitor dipyridamole had an IC 50 of 840 nM. The IC 50 value for dipyridamole and K m values for cAMP and cGMP agreed well with those reported previously, 10 and verified the structural integrity of the PDE11A4 preparation.
The IC 50 values of tadalafil, vardenafil, and sildenafil for PDE11A4 and PDE5A1 were then compared and fold selectivity values were calculated (Table 2) . IC 50 values for sildenafil, vardenafil, and tadalafil for PDE5 have been previously reported by our laboratory. 17 Of the three PDE5 inhibitors, vardenafil was the most selective for PDE5, with a 9300-fold selectivity ratio over PDE11A4. Sildenafil and tadalafil demonstrated selectivity ratios of 1000-and 40-fold, respectively. The 40-fold selectivity ratio of tadalafil for PDE5 over PDE11 reported here is significantly higher than that reported previously using PDE11A1, instead of PDE11A4. 12 This discrepancy could be due to differences in the kinetic properties of PDE11A1 and PDE11A4 that may arise from differences in N-terminal regulatory domains between these variants.
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Figure 3 A representative experiment demonstrating the determination of K m and maximal velocity values for cAMP and cGMP of purified human PDE11A4. K m values and maximal velocities were determined as described in Methods and Results. Average K m values for purified PDE11A4 were determined to be 0.97 mM for cGMP and 2.4 mM for cAMP and maximal velocities were 4-to 10-fold higher for cAMP than for cGMP. 
Concluding remarks
With the expanding use of PDE5 inhibitors in the treatment of erectile dysfunction and other maladies such as pulmonary hypertension, there is increased interest in understanding potential cross-reaction of these drugs with other proteins. Cross-reaction with proteins other than PDE5 would suggest the potential for side effects or safety issues. PDE11 is an obvious candidate for such a role since it is closely related to PDE5. 9 We now present biochemical potencies of sildenafil, vardenafil, and tadalafil for purified recombinant human PDE11A4 and establish the following order of potency for PDE11A4: tadalafilbvardenafil4sildenafil. Comparison of the fold selectivity for PDE5 over PDE11A4 for sildenafil (1000-fold selectivity) and vardenafil (9000-fold selectivity) reveals that these drugs are very unlikely to crossreact with PDE11A4 in patients taking the prescribed dosage of these medications. Tadalafil demonstrated a 40-fold selectivity for PDE5 over PDE11A4, making it also unlikely that tadalafil would crossreact with PDE11A4 in patients.
